Krina Patel, an expert in CAR T-cell therapies at MD Anderson Cancer Center, dives into the cutting-edge treatments for high-risk multiple myeloma. She discusses the latest clinical trial findings and how CAR-T therapies are tailored for specific high-risk subgroups. The conversation also touches on the potential of allogeneic CAR T-cell products. Additionally, there’s a focus on bispecific antibodies, with insights on resistance mechanisms and combination strategies that may enhance treatment efficacy. This is an enlightening listen for cancer care innovators!

Yi Lin from Mayo Clinic and Krina Patel from MD Anderson Cancer Center discuss key updates in multiple myeloma presented at ASH 2022. They talk about real-world experiences with access to CAR-T therapy, optimizing sequencing of therapies, ongoing clinical trials in high-risk disease, and more.